




Fig.1.

Chr/Clx/MASP-1/MASP-2/MASP-3




Fig. 2A.





Fig. 2B.



30




Fig.4.




Fig.5A.




Fig. 5B.




Fig.5C.




Fig. 6.

9/76






Fig. 7.


10/76

*Fig. 8A.*


11/76

*Fig. 8B.*

12/76

*Fig.8C.*

13/76

*Fig. 9.*




Fig. 10.

Binding of AbD Ab #40 & #60 to rat MASP2 polypeptides




Fig. 11.




Fig.12.




Fig. 13A.




Fig.13B.








Fig.14.


20/76

*Fig.15A.**Fig.15B.*



21/76

*Fig.16A.**Fig.16B.*


22/76

*Fig.17.*



23/76

*Fig.18.**Fig.19.*


24/76

*Fig.20.*

25/76

*Fig.21.**Fig.22.*

26/76

*Fig.23.*




Fig. 24A.




Fig.24B.




Fig. 25A.




Fig. 25B.




Fig. 25C.




Fig.26A.






Fig.26B.

33/76

*Fig.27A.**Fig.27B.*

34/76




Fig.28A.




Fig.28B.

35/76




Fig.28C.






Fig.28D.

36/76

*Fig.29A.**Fig.29B.*

37/76

Activation of C3 by thrombin

substrates







Fig.30

38/76

*Fig.31.*

39/76

*Fig.32A.**Fig.32B.*

Survival after *N. meningitidis* Serogroup A Z2491 infection




Fig.33.






Fig.34.


42/76

*Fig.35.*

43/76

*Fig.36.*

44/76

*Fig.37.*






Fig.38.

46/76


*Fig.39.*

47/76


Haemolysis of mannan-coated Murine RBC by human serum

*Fig.40.*


48/76

*Fig.41.*

49/76

*Fig.42.*

50/76

*Fig. 43.*

51/76

Time to onset of microvascular occlusion
following LPS injection (Schwarzman model)






Fig.44.


52/76

*Fig.45.*


53/76

*Fig.46.*


54/76

*Fig.47.*


55/76

*Fig.48.*


56/76

*Fig.49.*


57/76

*Fig.50.*


58/76

*Fig.51.*


59/76

*Fig.52.*


60/76

*Fig.53A.*


61/76

*Fig.53B.*


62/76

*Fig.53C.*


63/76

*Fig.54.*


64/76

*Fig.55A.*


65/76

*Fig.55B.*

66/76


*Fig.56.*

67/76

**Fig.57.**


68/76

Platelet Count Change from Baseline over Time

**Fig.58.**

69/76

LDH Change from Baseline over Time

*Fig.59.*

70/76

Change in Haptoglobin over Time



*Fig. 60.*


FIGURE 61



72/76

FIGURE 62A


Compassionate Use Patient # 1: CREATININE



73/76

FIGURE 62B


Compassionate Use Patient # 1: HAPTOGLOBIN



74/76

FIGURE 62C


Compassionate Use Patient # 1: HEMOGLOBIN



75/76

FIGURE 62D

Compassionate Use Patient # 1: LDH



76/76

FIGURE 62E

Compassionate Use Patient # 1: PLATELETS

